New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization

References

• Abdel-Aal MAA, Abdel-Aziz SA, Shaykoon MSA, Abuo-Rahma GE-DA. Towards anticancer fluoroquinolones: a review article. Arch Pharm 2019;352:e1800376.
   PubMed Web of Science ®Google Scholar
• Kaushik CP, Sangwan J, Luxmi R, et al. Design, synthesis, anticancer and antioxidant activities of amide linked 1,4-disubstituted 1,2,3-triazoles. J. Mol. Struct 2021;1226:129255.
   Web of Science ®Google Scholar
• Chekkara R, Gorla VR, Susithra E, et al. Design, synthesis and anticancer evaluation of 2-amino pyrimidine linked 7-azaindzole derivatives. Chem. Data Collect 2020;29:100513.
   Google Scholar
• El-Damasy AK, Haque MM, Park JW, et al. 2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAFV600E/C-RAF kinase inhibitory effects: design, synthesis, in vitro cell-based and oncogenic kinase assessments. Eur J Med Chem 2020;208:112756.
   PubMedGoogle Scholar
• Baglini E, Salerno S, Barresi E, et al. Multiple topoisomerase I (TopoI), topoisomerase II (TopoII) and Tyrosyl-DNA phosphodiesterase (TDP) inhibitors in the development of anticancer drugs. Eur J Pharm Sci 2021;156:105594.
   PubMed Web of Science ®Google Scholar
• Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol 2021;14:101174.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Wallberg KA. Principles of cancer treatment: impact on reproduction. Adv Exp Med Biol 2012;732:1–8.
   PubMed Web of Science ®Google Scholar
• Dong Y, Hu H, Sun Y, et al. Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors. Bioorg Med Chem Lett 2020;30:127610.
   PubMed Web of Science ®Google Scholar
• Chen J, Li D, Li W, et al. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors. Bioorg Med Chem 2018;26:3958–66.
   PubMed Web of Science ®Google Scholar
• Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007;12:34–42.
   PubMed Web of Science ®Google Scholar
• Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem 2014;57:7874–87.
   PubMed Web of Science ®Google Scholar
• Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. j Med Chem 2005;48:6523–43.
   PubMed Web of Science ®Google Scholar
• Bass AKA, El-Zoghbi MS, Nageeb E-SM, et al. Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. Eur. J. Med. Chem 2021; 209: 112904.
   PubMedGoogle Scholar
• Proschak E, Stark H, Merk D. Polypharmacology by design: a medicinal chemist's perspective on multitargeting compounds. J Med Chem 2019;62:420–44.
   PubMed Web of Science ®Google Scholar
• Raghavendra NM, Pingili D, Kadasi S, et al. Dual or multi-targeting inhibitors: the next generation anticancer agents. Eur J Med Chem 2018;143:1277–300.
   PubMed Web of Science ®Google Scholar
• Mohammed HHH, Abbas SH, Hayallah AM, et al. Novel urea linked ciprofloxacin-chalcone hybrids having antiproliferative topoisomerases I/II inhibitory activities and caspases-mediated apoptosis. Bioorganic Chem 2021;106:104422.
   PubMed Web of Science ®Google Scholar
• Drlica K. Mechanism of fluoroquinolone action. Curr Opin Microbiol 1999;2:504–8.
   PubMed Web of Science ®Google Scholar
• Shen LL, Baranowski J, Pernet AG. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA. Biochemistry 1989;28:3879–85.
   PubMed Web of Science ®Google Scholar
• Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3:430–40.
   PubMed Web of Science ®Google Scholar
• Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001;70:369–413.
   PubMed Web of Science ®Google Scholar
• Abdel-Aziz M, Park S-E, Abuo-Rahma GE-DAA, et al. Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity. Eur J Med Chem 2013;69:427–38.
   PubMed Web of Science ®Google Scholar
• Azéma J, Guidetti B, Dewelle J, et al. 7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents. Bioorg Med Chem 2009;17:5396–407.
   PubMed Web of Science ®Google Scholar
• Sissi C, Palumbo M. The quinolone family: from antibacterial to anticancer agents. Curr Med Chem Anticancer Agents 2003;3:439–50.
   PubMedGoogle Scholar
• Reuveni D, Halperin D, Shalit I, et al. Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects. Biochem Pharmacol 2008;75:1272–81.
   PubMedGoogle Scholar
• Yadav V, Varshney P, Sultana S, et al. Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation. BMC Cancer 2015;15:581.
   PubMed Web of Science ®Google Scholar
• Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: an underestimated truth. Biomed. Pharmacother 2019;111:934–46.
   PubMed Web of Science ®Google Scholar
• Mohammed HHH, Abuo-Rahma GE-DAA, Abbas SH, Abdelhafez E-SMN. Current trends and future directions of fluoroquinolones. Curr Med Chem 2019;26:3132–49.
   PubMedGoogle Scholar
• Ahadi H, Emami S. Modification of 7-piperazinylquinolone antibacterials to promising anticancer lead compounds: synthesis and in vitro studies. Eur J Med Chem 2020;187:111970.
   PubMed Web of Science ®Google Scholar
• Yogeeswari P, Sriram D, Kavya R, Tiwari S. Synthesis and in-vitro cytotoxicity evaluation of gatifloxacin Mannich bases. Biomed Pharmacother 2005;59:501–10.
   PubMedGoogle Scholar
• Nieto MJ, Alovero FL, Manzo RH, Mazzieri MR. Benzenesulfonamide analogs of fluoroquinolones. Antibacterial activity and QSAR studies. Eur J Med Chem 2005;40:361–9.
   PubMed Web of Science ®Google Scholar
• Gootz TD, McGuirk PR, Moynihan MS, Haskell SL. Placement of alkyl substituents on the C-7 piperazine ring of fluoroquinolones: dramatic differential effects on mammalian topoisomerase II and DNA gyrase. Antimicrob Agents Chemother 1994;38:130–3.
   PubMed Web of Science ®Google Scholar
• Foroumadi A, Emami S, Rajabalian S, et al. N-Substituted piperazinyl quinolones as potential cytotoxic agents: structure-activity relationships study. Biomed Pharmacother 2009;63:216–20.
   PubMedGoogle Scholar
• Azéma J, Guidetti B, Korolyov A, et al. Synthesis of lipophilic dimeric C-7/C-7-linked ciprofloxacin and C-6/C-6-linked levofloxacin derivatives. Versatile in vitro biological evaluations of monomeric and dimeric fluoroquinolone derivatives as potential antitumor, antibacterial or antimycobacterial agents. Eur J Med Chem 2011;46:6025–38.
   PubMed Web of Science ®Google Scholar
• Suresh N, Nagesh HN, Sekhar KVG, et al. Synthesis of novel ciprofloxacin analogues and evaluation of their anti-proliferative effect on human cancer cell lines. Bioorg Med Chem Lett 2013;23:6292–5.
   PubMed Web of Science ®Google Scholar
• Abdel-Aziz AA-M, El-Azab AS, Alanazi AM, et al. Synthesis and potential antitumor activity of 7-(4-substituted piperazin-1-yl)-4-oxoquinolines based on ciprofloxacin and norfloxacin scaffolds: in silico studies. J Enzyme Inhib Med Chem 2016;31:796–809.
   PubMed Web of Science ®Google Scholar
• Mohammed HHH, Abd El-Hafeez AA, Abbas SH, et al. New antiproliferative 7-(4-(N-substituted carbamoylmethyl)piperazin-1-yl) derivatives of ciprofloxacin induce cell cycle arrest at G2/M phase. Bioorg Med Chem 2016;24:4636–46.
   PubMed Web of Science ®Google Scholar
• Wang G, Liu W, Gong Z, et al. Design, synthesis, biological evaluation and molecular docking studies of new chalcone derivatives containing diaryl ether moiety as potential anticancer agents and tubulin polymerization inhibitors. Bioorg Chem 2020;95:103565.
   PubMed Web of Science ®Google Scholar
• Zhang E-H, Wang R-F, Guo S-Z, Liu B. An update on antitumor activity of naturally occurring chalcones, Evid Based Complement Alternat Med 2013;2013:815621.
   PubMed Web of Science ®Google Scholar
• Das M, Manna K. Chalcone scaffold in anticancer armamentarium: a molecular insight. J Toxicol 2016;2016:7651047.
   PubMed Web of Science ®Google Scholar
• Mirzaei H, Shokrzadeh M, Modanloo M, et al. New indole-based chalconoids as tubulin-targeting antiproliferative agents. Bioorg Chem 2017;75:86–98.
   PubMed Web of Science ®Google Scholar
• Yadav VR, Prasad S, Sung B, Aggarwal BB. The role of chalcones in suppression of NF-κB-mediated inflammation and cancer. Int Immunopharmacol 2011;11:295–309.
   PubMed Web of Science ®Google Scholar
• Singh P, Anand A, Kumar V. Recent developments in biological activities of chalcones: a mini review. Eur J Med Chem 2014;85:758–77.
   PubMed Web of Science ®Google Scholar
• Batovska DI, Todorova IT. Trends in utilization of the pharmacological potential of chalcones. Curr Clin Pharmacol 2010;5:1–29.
   PubMedGoogle Scholar
• Bonandi E, Christodoulou MS, Fumagalli G, et al. The 1,2,3-triazole ring as a bioisostere in medicinal chemistry. Drug Discov Today 2017;22:1572–81.
   PubMed Web of Science ®Google Scholar
• Xu Z, Zhao S-J, Liu Y. 1,2,3-Triazole-containing hybrids as potential anticancer agents: current developments, action mechanisms and structure-activity relationships. Eur J Med Chem 2019;183:111700.
   PubMed Web of Science ®Google Scholar
• Akhtar J, Khan AA, Ali Z, et al. Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities. Eur J Med Chem 2017;125:143–89.
   PubMed Web of Science ®Google Scholar
• Lal K, Yadav P. Recent advancements in 1,4-disubstituted 1H-1,2,3-triazoles as potential anticancer agents. Anticancer Agents Med Chem 2018;18:21–37.
   PubMed Web of Science ®Google Scholar
• Rashdan HRM, Gomha SM, El-Gendey MS, et al. Eco-friendly one-pot synthesis of some new pyrazolo[1,2-b]phthalazinediones with antiproliferative efficacy on human hepatic cancer cell lines. Green Chem. Lett. Rev 2018;11:264–74.
   Web of Science ®Google Scholar
• Gomha SM, Ahmed SA, Abdelhamid AO. Synthesis and Cytotoxicity evaluation of some novel thiazoles, thiadiazoles, and pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(1H)-ones incorporating triazole moiety. Molecules 2015;20:1357–76.
   PubMed Web of Science ®Google Scholar
• Dheer D, Singh V, Shankar R. Medicinal attributes of 1,2,3-triazoles: current developments. Bioorg Chem 2017;71:30–54.
   PubMed Web of Science ®Google Scholar
• Zhang B. Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids. Eur J Med Chem 2019;168:357–72.
   PubMed Web of Science ®Google Scholar
• Victoria Castelli M, Gabriel Derita M, Noelí López S. Novel antifungal agents: a patent review (2013 –present). Expert Opin Ther Pat 2017;27:415–26.
   PubMed Web of Science ®Google Scholar
• Emami S, Ghobadi E, Saednia S, Hashemi SM. Current advances of triazole alcohols derived from fluconazole: design, in vitro and in silico studies. Eur J Med Chem 2019;170:173–94.
   PubMed Web of Science ®Google Scholar
• Tian Y, Liu Z, Liu J, et al. Targeting the entrance channel of NNIBP: discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. Eur J Med Chem 2018;151:339–50.
   PubMed Web of Science ®Google Scholar
• Kaoukabi H, Kabri Y, Curti C, et al. Dihydropyrimidinone/1,2,3-triazole hybrid molecules: synthesis and anti-varicella-zoster virus (VZV) evaluation. Eur J Med Chem 2018;155:772–81.
   PubMed Web of Science ®Google Scholar
• Chu X-M, Wang C, Wang W-L, et al. Triazole derivatives and their antiplasmodial and antimalarial activities. Eur J Med Chem 2019;166:206–23.
   PubMed Web of Science ®Google Scholar
• Kalaria PN, Karad SC, Raval DK. A review on diverse heterocyclic compounds as the privileged scaffolds in antimalarial drug discovery. Eur J Med Chem 2018;158:917–36.
   PubMed Web of Science ®Google Scholar
• Keri RS, Patil SA, Budagumpi S, Nagaraja BM. Triazole: a promising antitubercular agent. Chem Biol Drug Des 2015;86:410–23.
   PubMed Web of Science ®Google Scholar
• Zhang S, Xu Z, Gao C, et al. Triazole derivatives and their anti-tubercular activity. Eur J Med Chem 2017;138:501–13.
   PubMed Web of Science ®Google Scholar
• M. M A. 1,2,3‐Triazole hybrids as anticancer agents: a review. Arch. Pharm 2022;355:2100158.
   Google Scholar
• Oubella A, Bimoussa A, Oussidi AN, et al. New 1,2,3-triazoles from(R)-carvone: synthesis, DFTMechanistic study and in vitro cytotoxic evaluation. Molecules 2022;27:769.
   PubMed Web of Science ®Google Scholar
• Ashour HF, Abou-zeid LA, El-Sayed MA-A, Selim KB. 1,2,3-Triazole-chalcone hybrids: synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226. Eur J Med Chem 2020;189:112062.
   PubMed Web of Science ®Google Scholar
• Yan W, Xiangyu C, Ya L, et al. An orally antitumor chalcone hybrid inhibited HepG2 cells growthand migration as the tubulin binding agent. Invest New Drugs 2019;37:784–90.
   PubMed Web of Science ®Google Scholar
• Gurrapu N, Kumar EP, Kolluri PK, et al. Synthesis, biological evaluation and molecular docking studies of novel 1,2,3-triazole tethered chalcone hybrids as potential anticancer agents. J. Mol. Struct 2020;1217:128356.
   Google Scholar
• Rahulan KM, Balamurugan S, Meena KS, et al. Synthesis and nonlinear optical absorption of novel chalcone derivative compounds. Opt. Laser Technol 2014;56:142–5.
   Web of Science ®Google Scholar
• Balamurugan S, Nithyanandan S, Selvarasu C, et al. Photophysical and photochemical investigations on triazole ring linked chalcone containing polymethacrylates. Polymer 2012;53:4104–11.
   Web of Science ®Google Scholar
• McPherson JC, Runner R, Buxton TB, et al. Synthesis of osteotropic hydroxybisphosphonate derivatives of fluoroquinolone antibacterials. Eur J Med Chem 2012;47:615–8.
   PubMed Web of Science ®Google Scholar
• Keepers YP, Pizao PE, Peters GJ, et al. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer Clin Oncol 1991;27:897–900.
   Google Scholar
• Perez RP, Godwin AK, Handel LM, Hamilton TC. A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur J Cancer 1993;29:395–9.
   Google Scholar
• Iqbal H, Prabhakar V, Sangith A, et al. Synthesis, anti- inflammatory and antioxidant activity of ring-A-monosubstituted chalcone derivatives. Med. Chem. Res 2014;23:4383–94.
   Web of Science ®Google Scholar
• Worrell BT, Malik JA, Fokin VV. Direct evidence of a dinuclear copper intermediate in Cu(I)-catalyzed azide-alkyne cycloadditions. Science 2013;340:457–60.
   PubMed Web of Science ®Google Scholar
• https://dtp.cancer.gov.
   Google Scholar
• Marwa Ali A. Fathi AA, Abd El-Hafeez DA, Abbas SH, Montano MM. Mohamed Abdel-Aziz, 1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities. Bioorganic Chem 2019;84:153–60.
   Web of Science ®Google Scholar
• Mekkawy AI, Naguib YW, Alhaj-Suliman SO, et al. Paclitaxel anticancer activity is enhanced by the MEK 1/2 inhibitor PD98059 in vitro and by PD98059-loaded nanoparticles in BRAFV600E melanoma-bearing mice. Int J Pharm 2021;606:120876.
   PubMedGoogle Scholar
• Popp HD, Brend S, Hofmann W-K, Fabarius A. Immunofluorescence microscopy of γH2AX and 53BP1 for analyzing the formation and repair of DNA double-strand breaks. J Vis Exp 2017;129:e56617.
   Google Scholar
• Ryu MJ, Chung HS. [10]-Gingerol induces mitochondrial apoptosis through activation of MAPK pathway in HCT116 human colon cancer cells. In Vitro Cell Dev Biol Anim 2015;51:92–101.
   PubMedGoogle Scholar
• Ahmed FF, Abd El-Hafeez AA, Abbas SH, et al. New 1,2,4-triazole-chalcone hybrids induce caspase-3 dependent apoptosis in A549 human lung adenocarcinoma cells. Eur J Med Chem 2018;151:705–22.
   PubMed Web of Science ®Google Scholar
• P. Giannakakou DL, Sackett Y-K, Kang Z, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118–25.
   PubMedGoogle Scholar
• Sinha S, Field JJ, Miller JH. Use of substitute Nonidet P-40 nonionic detergents in intracellular tubulin polymerization assays for screening of microtubule targeting agents. Biochem Cell Biol 2017;95:379–84.
   PubMedGoogle Scholar